Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on October 1, 2009
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyp116
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/12/791    most recent
hyp116v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sun, Q.
Right arrow Articles by Zhang, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, Q.
Right arrow Articles by Zhang, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press. All rights reserved

Irinotecan Plus Capecitabine as a Second-line Treatment after Failure of 5-Fluorouracil and Platinum in Patients with Advanced Gastric Cancer

Qing Sun1, Meng Hang1, Wei Xu1, Weidong Mao2, Xiaosheng Hang3, Maoquan Li4 and Jiaxing Zhang4

1 Department of Medical Oncology, Wuxi 2nd People's Hospital, Nanjing Medical University
2 Department of Medical Oncology, Jiangyin People's Hospital, Medical School of Nantong University
3 Department of Medical Oncology, Wuxi Cancer Hospital, Medical School of Suzhou University, Jiangsu
4 Radiology Clinical Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, PR China

For reprints and all correspondence: Maoquan Li, Radiology Clinical Center, Shanghai Tenth People's Hospital of Tongji University, No. 301, Yanchang Rd, Shanghai 200072, PR China. E-mail: drmaoquan.li.md{at}gmail.com

Received June 24, 2009; accepted August 10, 2009

Objective: This Phase II study was conducted to evaluate the effects of irinotecan plus capecitabine in patients with advanced gastric cancer (AGC) who had received a first-line therapy of 5-fluorouracil/platinum regimen.

Methods: Patients received capecitabine 1000 mg/m2 b.i.d. on days 1–14 followed by a 7-day rest period, and irinotecan 100 mg/m2 was administered through a 90 min intravenous infusion on days 1 and 8, based on a 3-week cycle.

Results: Forty-six (95.8%) of the 48 patients were assessable for response. Thirteen cases of partial response were confirmed, response rate of 27.1% (95% CI, 14.5–39.7%). The median follow-up period was 25.2 months. The median time to progression and overall survival for all patients were 4.1 months (95% CI, 3.4–4.8 months) and 7.6 months (95% CI, 5.1–10.1 months). Grade 3 diarrhea and hand-foot syndrome occurred in eight (17.4%) and two (4.3%) patients, respectively. The most common Grade 3/4 hematological adverse event was neutropenia in four (8.7%) patients. There were no treatment-related deaths during this study.

Conclusion: Irinotecan plus capecitabine was a relatively active and tolerable regimen as a second-line chemotherapy for AGC. Further investigation of this regimen is warranted, including the addition of new biological agents such as bevacizumab or cetuximab to improve the salvage regimen.

Key Words: advanced gastric cancer • second-line chemotherapy • irinotecan • capecitabine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.